Crispr Therapeutics AG (CRSP) Insider Trading
- $28,147,755.86
- $317,726,279.25
- March 11, 2025
- Samarth Kulkarni
| Trader Name | Date | Title | Amount | Price | Type | Total Value |
|---|---|---|---|---|---|---|
| April 28, 2017 | Insider | 21,639 | $16.78 | Sell | $363,102.42 | |
| April 27, 2017 | Insider | 5,481 | $16.76 | Sell | $91,861.56 | |
| April 25, 2017 | Insider | 11,615 | $16.78 | Sell | $194,899.70 | |
| April 20, 2017 | Insider | 10,177 | $17.71 | Sell | $180,234.67 | |
| April 20, 2017 | CEO | 50,000 | $17.88 | Sell | $894,000.00 | |
| Oct. 24, 2016 | Director | 66,500 | $14.00 | Buy | $931,000.00 | |
| Oct. 24, 2016 | Major Shareholder | 800,150 | $14.00 | Buy | $11,202,100.00 |
Insiders are both buying and selling Crispr Therapeutics AG stock.
The insider traders at Crispr Therapeutics AG are: Samarth Kulkarni, Rodger Novak, Kurt Von Emster, Bradley J Phd Bolzon, Corp /De/ Celgene, Tyler Dylan-Hyde, Pablo J Cagnoni, Lawrence Otto Klein, James R Kasinger, Thomas Woiwode, Vertex Pharmaceuticals (Europe, Julianne Bruno, Michael John Tomsicek, John Greene, Simeon George, James R. Kasinger, Tony W Ho, Tony W. Ho, Bradley J. Phd Bolzon, Versant Venture Capital V, L.P, Aktiengesellschaft Bayer, and Raju Prasad
The most active insider trader at Crispr Therapeutics AG is Samarth Kulkarni with 36 trades.
Kurt Von Emster has sold the most Crispr Therapeutics AG stock with a total value of $68,130,025.01.
Aktiengesellschaft Bayer has bought the most Crispr Therapeutics AG stock with a total value of $23,999,976.00.
The most recent insider trade for Crispr Therapeutics AG was on March 11, 2025.
The single biggest insider buy for Crispr Therapeutics AG was from Aktiengesellschaft Bayer with a total value of $11,999,988.00 on Jan. 5, 2018.
The single biggest insider sell for Crispr Therapeutics AG was from Kurt Von Emster with a total value of $35,353,500.00 on May 14, 2018.